Sun Pharma share price: targets rise after Organon deal

What moved the stock

Sun Pharmaceutical Industries Ltd shares were trading flat on Tuesday after a sharp rise in the previous session. On Monday, the stock gained 7.03% to close at Rs 1,733.80 on the BSE following the Organon announcement. In morning deals on the NSE, the stock was seen around Rs 1,740, up 7.33% at one point. Another market update showed the last close at Rs 1,733.50, with a 5-day change of +3.89% and a 1st Jan change of +0.80%.

The deal at the centre of the rally

Sun Pharma has entered into a definitive agreement to acquire US-based Organon & Co in an all-cash transaction. The company will acquire 100% of Organon’s issued and outstanding shares at $14.00 per share. The terms imply an equity value of $1.99 billion and an enterprise value (EV) of $11.75 billion. Market participants described it as the biggest takeover by an Indian pharmaceutical company and the largest overseas acquisition by an Indian pharma company at the stated enterprise value.

HDFC Securities raises target, keeps Buy

HDFC Securities maintained a positive stance on Sun Pharma and reiterated its ‘Buy’ call while raising the target price. The brokerage increased its target to Rs 2,030 from Rs 2,000. HDFC Securities also laid out its expectations for the deal’s financial impact, saying it expects the transaction to be sales/EBITDA/PAT accretive by 80%/82%/27% in FY28. It added that the lower earnings growth is on account of higher interest costs and depreciation.

Emkay: concerns addressed, valuation multiple remains key

Emkay said most investor concerns around growth in the acquired company, leverage, and EPS accretion were addressed during Sun Pharma’s conference call. It flagged that the remaining key question is the fair multiple for Sun Pharma going forward. Emkay suggested a ‘Buy’ rating with a target of Rs 2,100.

HDFC Institutional Equities flags near-term overhang

HDFC Institutional Equities said it sees the growth trend for the combined entity falling to mid-single digit from 10-12% for Sun Pharma alone. It called this a major near-term overhang. It also highlighted the operational and financial focus areas investors may track, including a scale-up in a competitive biosimilar business, growth revival in the women’s health portfolio, and servicing of $1.5 billion debt. This brokerage also suggested a ‘Buy’ with a target price of Rs 2,030.

Nirmal Bang and Nuvama: higher targets and synergy focus

Nirmal Bang Institutional Equities suggested a target of Rs 2,320 on the stock, indicating 34% potential upside. It noted that Organon consolidation upside is not yet baked into its target price, and said a successful closing and integration would provide further upside. Nuvama said the deal unlocks over $150 million in synergies over two to four years and paves the way for Sun’s entry into a scaled biosimilars platform growing at 13% compounded annually. Nuvama added that proforma numbers show over 40% EPS accretion to Sun Pharma’s current FY28 estimate, and retained ‘BUY’ with a revised target of Rs 2,000 (earlier Rs 1,875). It also said the stock trades at 29 times/25 times FY27E/28E EPS.

Macquarie: path to net debt-free in 3-4 years

Macquarie Capital’s pharma and healthcare research analyst Kunal Dhamesha said Organon is a strategic fit for Sun Pharma, especially after the target’s valuation correction. He said the combined operating cash flows of both companies should be sufficient to service debt comfortably. Dhamesha added Sun Pharma could return to a net debt-free position within the next three to four years. He also said the share of innovative business revenue may rise to 27% of the merged entity.

Analysts’ consensus: targets imply upside from last close

Market data in the provided updates showed a mean consensus rating of BUY across 32 analysts. The last close price was listed at Rs 1,733.50. The average target price was shown as Rs 1,962.59, implying a +13.22% spread versus the average target, and the high price target was Rs 2,392.00.

Key numbers to track from the announcement

The market reaction and subsequent brokerage notes anchored around deal valuation, expected accretion, and leverage. Investors also appeared to weigh the near-term growth profile for the combined entity against synergy estimates and longer-term portfolio positioning.

Why the story matters for Sun Pharma investors

The immediate stock move reflects how quickly deal announcements can reset expectations for earnings mix, scale, and capital structure. Multiple brokerages kept ‘Buy’ ratings while differing on target prices, indicating broad support but varied assumptions on integration and valuation. At the same time, at least one brokerage framed a near-term overhang around a slower growth trajectory for the combined entity versus Sun Pharma on a standalone basis. The range of targets cited in the updates spans Rs 2,000 to Rs 2,320, while consensus data shows an average target of Rs 1,962.59 against a last close around Rs 1,733.50.

Conclusion

Sun Pharma’s sharp Monday gain followed the signing of a definitive agreement to acquire Organon in an all-cash deal at $14 per share, with an implied EV of $11.75 billion. Brokerages largely stayed constructive, raising targets and detailing expected accretion, while also pointing to growth dilution, debt servicing, and execution as key variables investors will monitor.